Global Outlook for the Non-invasive Prenatal Testing Market 2021-2030

DUBLIN, October 29, 2021–(BUSINESS WIRE)–The “Non-invasive Prenatal Testing Global Market Report 2021: COVID-19 Growth and Change to 2030” report has been added to ResearchAndMarkets.com’s offering.

The global non-invasive prenatal testing market is expected to grow from $2.17 billion in 2020 to $2.43 billion in 2021 at a compound annual growth rate (CAGR) of 12%.

The growth is mainly due to the companies resuming their operations and adapting to the new normal while recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The market is expected to reach $4.02 billion in 2025 at a CAGR of 13.4%.

The non-invasive prenatal testing market covered in this report is segmented by type into consumables, instruments.

It is also segmented by end user into hospital, diagnostic labs; by instruments into NGS systems, PCR instruments, microarrays, ultrasound devices, others(centrifuges, UV systems, incubators, microscopes); by consumables into assay kits &reagents, disposables and by application into trisomy, microdeletion, genetics, Rh factor.

The ethical hurdles in the non-invasive prenatal testing (NIPT) market have led to a range of ethical issues in terms of sex selection or aborting babies with chromosomal abnormality. Determining the sex of the fetus or knowing if the baby has an abnormality at an earlier stage led to abortions and resulted as an ethical issue which further led to strict regulations on using such devices. According to Department of Health (UK), there were 3,213 abortions in England and Wales from which 37% of the total abortions consisted of chromosomal abnormality and 80% of the abortions were performed under 10 weeks of pregnancy. These hurdles will restrain the non-invasive prenatal testing market.

Next generation sequencing has increased the throughput, scalability, and speed, and further enables researchers to perform a wide range of applications and study biological systems at a higher level. Next generation sequencing is a platform that has enabled sequencing of thousands to millions of DNA molecules simultaneously.

Story continues

The manufacturers have introduced this technology to reduce the time and money required and optimizes the output to generate results regarding genome, DNA testing. Major companies such as Illumina, Eurofins, Natera, Roche, and Annoroad have implemented this technology in non-invasive prenatal testing. CFDA (China Food and Drug Administration) has approved the medical instrument product registration of NGS instrument NextSeq 550AR produced by Annoroad.

In June 2019, Invitae, a USA based medical genetics company acquired Singular Bio for $55M. This acquisition will further strengthen Invitae’s ability to bring genetic information into mainstream medical care. Singular Bio, a USA based company specializing in single-molecule, cell-free DNA…